{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:39:08Z","timestamp":1793039948420,"version":"4.5.0"},"reference-count":58,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Nanjing University Innovation Program for the Ph.D. candidate","id":[{"id":"https:\/\/ror.org\/01rxvg760","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472820"],"award-info":[{"award-number":["81472820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700037"],"award-info":[{"award-number":["81700037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773255"],"award-info":[{"award-number":["81773255"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Jiangsu Province of China","award":["BK20171098"],"award-info":[{"award-number":["BK20171098"]}]},{"name":"Science and Technology Innovation Foundation of Nanjing University","award":["14913414"],"award-info":[{"award-number":["14913414"]}]},{"name":"Research Foundation for Advanced Talents of Chifeng Municipal Hospital","id":[{"id":"https:\/\/ror.org\/02j136k79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,11,23]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In addition to directly lysing tumors, oncolytic viruses also induce antitumor immunity by recruiting and activating immune cells in the local tumor microenvironment. However, the activation of the immune cells induced by oncolytic viruses is always accompanied by high-level expression of immune checkpoints in these cells, which may reduce the efficacy of the oncolytic viruses. The aim of this study is to arm the oncolytic vaccinia virus (VV) with immune checkpoint blockade to enhance its antitumor efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Through homologous recombination with the parental VV, an engineered VV-scFv-TIGIT was produced, which encodes a single-chain variable fragment (scFv) targeting T-cell immunoglobulin and ITIM domain (TIGIT). The antitumor efficacy of the VV-scFv-TIGIT was explored in several subcutaneous and ascites tumor models. The antitumor efficacy of VV-scFv-TIGIT combined with programmed cell death 1 (PD-1) or lymphocyte-activation gene 3 (LAG-3) blockade was also investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The VV-scFv-TIGIT effectively replicated in tumor cells and lysed them, and prompt the infected tumor cells to secret the functional scFv-TIGIT. Compared with control VV, intratumoral injection of VV-scFv-TIGIT in several mouse subcutaneous tumor models showed superior antitumor efficacy, accompanied by more T cell infiltration and a higher degree of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells activation. Intraperitoneal injection of VV-scFv-TIGIT in a mouse model of malignant ascites also significantly improved T cell infiltration and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell activation, resulting in more than 90% of the tumor-bearing mice being cured. Furthermore, the antitumor immune response induced by VV-scFv-TIGIT was dependent on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells which mediated a long-term immunological memory and a systemic antitumor immunity against the same tumor. Finally, the additional combination of PD-1 or LAG-3 blockade further enhanced the antitumor efficacy of VV-scFv-TIGIT, increasing the complete response rate of tumor-bearing mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Oncolytic virotherapy using engineered VV-scFv-TIGIT was an effective strategy for cancer immunotherapy. Administration of VV-scFv-TIGIT caused a profound reshaping of the suppressive tumor microenvironment from \u2018cold\u2019 to \u2018hot\u2019 status. VV-scFv-TIGIT also synergized with PD-1 or LAG-3 blockade to achieve a complete response to tumors with poor response to VV or immune checkpoint blockade monotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-002843","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T12:08:24Z","timestamp":1640261304000},"page":"e002843","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":71,"title":["An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-1200","authenticated-orcid":false,"given":"Shuguang","family":"Zuo","sequence":"first","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"},{"name":"Laboratory for Translational Medicine, Chifeng Municipal Hospital, Chifeng Clinical Medical School, Inner Mongolia Medical University, Chifeng, Inner Mongolia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wei","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkai","family":"Kong","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"He","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibing","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Wu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwu","family":"Wei","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"2025100305152476000_9.12.e002843.1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0015"},{"key":"2025100305152476000_9.12.e002843.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"2025100305152476000_9.12.e002843.3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0495-7"},{"key":"2025100305152476000_9.12.e002843.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00195","article-title":"Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer","volume":"7","author":"Howells","year":"2017","journal-title":"Front Oncol"},{"key":"2025100305152476000_9.12.e002843.5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00866"},{"key":"2025100305152476000_9.12.e002843.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70107-4"},{"key":"2025100305152476000_9.12.e002843.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1932"},{"key":"2025100305152476000_9.12.e002843.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"2025100305152476000_9.12.e002843.9","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0458-z"},{"key":"2025100305152476000_9.12.e002843.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377"},{"key":"2025100305152476000_9.12.e002843.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.10.007"},{"key":"2025100305152476000_9.12.e002843.12","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1091-2"},{"key":"2025100305152476000_9.12.e002843.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0014-6"},{"key":"2025100305152476000_9.12.e002843.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1529"},{"key":"2025100305152476000_9.12.e002843.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"2025100305152476000_9.12.e002843.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2006.10.010"},{"key":"2025100305152476000_9.12.e002843.17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2025100305152476000_9.12.e002843.18","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.312"},{"key":"2025100305152476000_9.12.e002843.19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.omto.2019.10.003","article-title":"Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1","volume":"15","author":"Zhu","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"2025100305152476000_9.12.e002843.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"2025100305152476000_9.12.e002843.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1638"},{"key":"2025100305152476000_9.12.e002843.22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01677-19"},{"key":"2025100305152476000_9.12.e002843.23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1220467"},{"key":"2025100305152476000_9.12.e002843.24","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2011.176"},{"key":"2025100305152476000_9.12.e002843.25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00202","article-title":"Oncolytic viruses-natural and genetically engineered cancer immunotherapies","volume":"7","author":"Jhawar","year":"2017","journal-title":"Front Oncol"},{"key":"2025100305152476000_9.12.e002843.26","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2025100305152476000_9.12.e002843.27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060877","article-title":"Dnam-1 and the TIGIT\/PVRIG\/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy","volume":"11","author":"Sanchez-Correa","year":"2019","journal-title":"Cancers"},{"key":"2025100305152476000_9.12.e002843.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.009"},{"key":"2025100305152476000_9.12.e002843.29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80445"},{"key":"2025100305152476000_9.12.e002843.30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81187"},{"key":"2025100305152476000_9.12.e002843.31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","article-title":"Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)","volume":"38","author":"Rodriguez-Abreu","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100305152476000_9.12.e002843.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2246-5"},{"key":"2025100305152476000_9.12.e002843.33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0628"},{"key":"2025100305152476000_9.12.e002843.34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1442169","article-title":"Heating it up: oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies","volume":"7","author":"Gujar","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100305152476000_9.12.e002843.35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14712598.2020.1729351","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors","volume":"20","author":"Chiu","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025100305152476000_9.12.e002843.36","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic virus combination therapy: killing one bird with two stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol Ther"},{"key":"2025100305152476000_9.12.e002843.37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754"},{"key":"2025100305152476000_9.12.e002843.38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2019.07.003","article-title":"Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance","volume":"51","author":"Rivadeneira","year":"2019","journal-title":"Immunity"},{"key":"2025100305152476000_9.12.e002843.39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7992"},{"key":"2025100305152476000_9.12.e002843.40","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol Ther"},{"key":"2025100305152476000_9.12.e002843.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"2025100305152476000_9.12.e002843.42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100305152476000_9.12.e002843.43","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.ymthe.2019.07.019","article-title":"Recombinant adenovirus expressing a soluble fusion protein PD-1\/CD137L subverts the suppression of CD8+ T cells in HCC","volume":"27","author":"Zhang","year":"2019","journal-title":"Mol Ther"},{"key":"2025100305152476000_9.12.e002843.44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025100305152476000_9.12.e002843.45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100305152476000_9.12.e002843.46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI98047"},{"key":"2025100305152476000_9.12.e002843.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0"},{"key":"2025100305152476000_9.12.e002843.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0575"},{"key":"2025100305152476000_9.12.e002843.49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"2025100305152476000_9.12.e002843.50","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2025100305152476000_9.12.e002843.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"2025100305152476000_9.12.e002843.52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31184"},{"key":"2025100305152476000_9.12.e002843.53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804211"},{"key":"2025100305152476000_9.12.e002843.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer"},{"key":"2025100305152476000_9.12.e002843.55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"2025100305152476000_9.12.e002843.56","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"2025100305152476000_9.12.e002843.57","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100305152476000_9.12.e002843.58","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:15:35Z","timestamp":1759493735000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,23]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/jitc-2021-002843"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002843","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}